Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:20
  • preuzimanja u poslednjih 30 dana:13

Sadržaj

članak: 3 od 59  
Back povratak na rezultate
2020, vol. 54, br. 4, str. 143-148
Novi lekovi - značaj slučajnog otkrića
Univerzitet u Novom Sadu, Medicinski fakultet, Katedra za farmaciju

e-adresamaja.milanovic@mf.uns.ac.rs
Ključne reči: otkriće leka; razvoj leka; repozicioniranje leka
Sažetak
Ključni element slučajnog otkrića (serendipity) nije samo sreća već je i razmišljanje. Proces otkrića uključuje zapažanje i prepoznavanje potencijala na osnovu znanja i iskustva. Slučajna otkrića su česta u oblasti biomedicinskih nauka. Znatan broj lekova otkriven je zahvaljujući srećnom slučaju. Za otkriće grupe lekova kojima pripadaju antimikrobni agensi, lekovi koji deluju na centralni nervni sistem i antineoplastici najzaslužnija su slučajna otkrića. Osim u tradicionalnom, iracionalnom pristupu dizajnu lekova, slučajna otkrića nisu zaobišla ni neke od savremenih pristupa poput strategije repozicioniranja lekova (drug repositioning) i razvoja multitarget antitumorskih agenasa. Slučajna otkrića novih lekova mogu se podeliti na laboratorijska i klinička, u zavisnosti od toga u kojoj etapi razvoja leka i pod kojim okolnostima je došlo do spoja nepredviđenih događaja i znanja i sposobnosti istraživača. Otkric'e novog leka zahteva izvrsnost u nauci u kojoj ključno mesto imaju prosvec'enost, sloboda i otvorenost uma istraživača da deluje, kritički razmišlja, rizikuje i izaziva dogme.
Reference
*** (2019) WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index. Oslo: Norwegian Institute of Public Health, https://www.whocc.no/atc_ddd_index/
Ashburn, T.T., Thor, K.B. (2004) Drug repositioning: Identifying and developing new uses for existing drugs. Nature Reviews Drug Discovery, 3: 673-83
Bai, R.Y., Staedtke, V., Rudin, C.M., Bunz, F., Riggins, G.J. (2015) Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis. Neuro-Oncology, 17: 545-54
Ban, T.A. (2006) The role of serendipity in drug discovery. Drug Discovery and Proof of Concept, 8: 335-44
Braña, M.F., Sánchez-Migallón, A. (2006) Anticancer drug discovery and pharmaceutical chemistry: A history. Clin Transl Oncol, 8: 717-28
Brodie, M.J. (2010) Antiepileptic drug therapy the story so far. Seizure, 19: 650-5
Campanario, J.M. (1996) Using citation classics to study the incidence of serendipity in scientific discovery. Scientometrics, 37: 3-24
Cheung-Ong, K., Giaever, G., Nislow, C. (2013) DNA-damaging agents in cancer chemotherapy: Serendipity and chemical biology. Chemistry & Biology, 20: 648-59
Colman, D.R. (2006) The three princes of Serendip: Notes on a mysterious phenomenon. McGill Journal of Medicine, 9: 161-3
Crump, A., Ōmura, S. (2011) Ivermectin, 'wonder drug' from Japan: The human use perspective. Proc Jpn Acad Ser B Phys Biol Sci, 87: 13-28
de Rond, M. (2014) The structure of serendipity. Culture and Organization, 20: 342-58
Desborough, M.J.R., Keeling, D.M. (2017) The aspirin story: From willow to wonder drug. British Journal of Haematology, 177: 674-83
Duffin, J. (2000) Poisoning the spindle: Serendipity and discovery of the anti-tumor properties of the Vinca alkaloids. Canadian Bulletin of Medical History, 17: 155-92
Fu, R.-.G., Sun, Y., Sheng, W.-.B., Liao, D.-.F. (2017) Designing multi-targeted agents: An emerging anticancer drug discovery paradigm. European Journal of Medicinal Chemistry, 136: 195-211
Geromichalos, G.D., Alifieris, C.E., Geromichalou, E.G., Trafalis, D.T. (2016) Overview on the current status of virtual high-throughput screening and combinatorial chemistry approaches in multi-target anticancer drug discovery; Part I. J BUON, 21: 764-79
Hargrave-Thomas, E., Yu, B., Reynisson, J. (2012) Serendipity in anticancer drug discovery. World Journal of Clinical Oncology, 3: 1-6
Jeste, D.V., Gillin, J.C., Wyatt, R.J. (1979) Serendipity in biological psychiatry: A myth?. Arch Gen Psychiatry, 36: 1173-8
Klajn, I., Šipka, M. (2006) Veliki rečnik stranih reči i izraza. Novi Sad: Prometej, I izd
Klein, D.F. (2008) The loss of serendipity in psychopharmacology. JAMA, 299: 1063-5
Kubinyi, H. (1999) Chance favors the prepared mind: From serendipity to rational drug design. Journal of Receptors and Signal Transduction, 19: 15-39
Langedijk, J., Mantel-Teeuwisse, A.K., Slijkerman, D.S., Schutjens, M.H. (2015) Drug repositioning and repurposing: Terminology and definitions in literature. Drug Discovery Today, 20: 1027-34
Li, H., Xiao, H., Lin, L., et al. (2014) Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: Discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface. Journal of Medicinal Chemistry, 57: 632-41
López-Muñoz, F., Baumeister, A.A., Hawkins, M.F., Alamo, C. (2012) The role of serendipity in the discovery of the clinical effects of psychotropic drugs: Beyond of the myth. Actas Esp Psiquiatr, 40: 34-42
Malaviya, A.N. (2016) Landmark papers on the discovery of methotrexate for the treatment of rheumatoid arthritis and other systemic inflammatory rheumatic diseases: A fascinating story. International Journal of Rheumatic Diseases, 19: 844-51
Milovanović, D.R., Janković, S.M., Ružić-Zečević, D., Folić, M., Rosić, N., Jovanović, D., Baskić, D., Vojinović, R., Mijailović, Ž., Sazdanović, P. (2020) Lečenje koronavirusne bolesti (COVID-19). Medicinski časopis, vol. 54, br. 1, str. 23-43
Pina, A.S., Hussain, A., Roque, A.C. (2009) An historical overview of drug discovery. Methods Mol Biol, 572: 3-12
Sardana, D., Zhu, C., Zhang, M., Gudivada, R.C., Yang, L., Jegga, A.G. (2011) Drug repositioning for orphan diseases. Briefings in Bioinformatics, 12: 346-56
Sneader, W. (2005) Drugs discovered through serendipitous observations involving humans. u: Sneader W. [ur.] Drug Discovery: A History, Chichester: John Wiley & Sons, 432-7
Sneader, W. (2005) Drugs Discovered through serendipity in the laboratory. u: Sneader W. [ur.] Drug discovery: a history, Chichester: John Wiley & Sons, 438-45
Vargesson, N. (2015) Thalidomide-induced teratogenesis: History and mechanisms. Birth Defects Res C Embryo Today, 105: 140-56
Wardrop, D., Keeling, D. (2008) The story of the discovery of heparin and warfarin. British Journal of Haematology, 141: 757-63
Yella, J.K., Yaddanapudi, S., Wang, Y., Jegga, A.G. (2018) Changing Trends in Computational Drug Repositioning. Pharmaceuticals (Basel), 11: 57
Zaffiri, L., Gardner, J., Toledo-Pereyra, L.H. (2012) History of antibiotics: From salvarsan to cephalosporins. Journal of Investigative Surgery, 25: 67-77
Zins, G.R. (1988) The history of the development of minoxidil. Clinics in Dermatology, 6: 132-47
 

O članku

jezik rada: srpski
vrsta rada: pregledni članak
DOI: 10.5937/mckg54-28546
primljen: 25.09.2020.
prihvaćen: 20.12.2020.
objavljen u SCIndeksu: 29.03.2021.

Povezani članci

Nema povezanih članaka